JP2025515237A5 - - Google Patents
Info
- Publication number
- JP2025515237A5 JP2025515237A5 JP2025513209A JP2025513209A JP2025515237A5 JP 2025515237 A5 JP2025515237 A5 JP 2025515237A5 JP 2025513209 A JP2025513209 A JP 2025513209A JP 2025513209 A JP2025513209 A JP 2025513209A JP 2025515237 A5 JP2025515237 A5 JP 2025515237A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- amino acid
- seq
- acid sequence
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (21)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263364328P | 2022-05-06 | 2022-05-06 | |
| US202263364331P | 2022-05-06 | 2022-05-06 | |
| US63/364,331 | 2022-05-06 | ||
| US63/364,328 | 2022-05-06 | ||
| US202263381131P | 2022-10-26 | 2022-10-26 | |
| US202263381132P | 2022-10-26 | 2022-10-26 | |
| US63/381,131 | 2022-10-26 | ||
| US63/381,132 | 2022-10-26 | ||
| US202263424945P | 2022-11-13 | 2022-11-13 | |
| US63/424,945 | 2022-11-13 | ||
| US202263383695P | 2022-11-14 | 2022-11-14 | |
| US63/383,695 | 2022-11-14 | ||
| US202263385957P | 2022-12-02 | 2022-12-02 | |
| US63/385,957 | 2022-12-02 | ||
| US202363478650P | 2023-01-05 | 2023-01-05 | |
| US63/478,650 | 2023-01-05 | ||
| US202363480903P | 2023-01-20 | 2023-01-20 | |
| US63/480,903 | 2023-01-20 | ||
| US202363492206P | 2023-03-24 | 2023-03-24 | |
| US63/492,206 | 2023-03-24 | ||
| PCT/US2023/066714 WO2023215910A1 (en) | 2022-05-06 | 2023-05-05 | Antigen binding molecules targeting sars-cov-2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025515237A JP2025515237A (ja) | 2025-05-13 |
| JP2025515237A5 true JP2025515237A5 (enExample) | 2026-05-15 |
Family
ID=86732784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025513209A Pending JP2025515237A (ja) | 2022-05-06 | 2023-05-05 | Ｓａｒｓ－ｃｏｖ－２を標的とする抗原結合分子 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11993644B2 (enExample) |
| EP (1) | EP4519310A1 (enExample) |
| JP (1) | JP2025515237A (enExample) |
| KR (1) | KR20250054840A (enExample) |
| CN (1) | CN121127489A (enExample) |
| AU (1) | AU2023265164A1 (enExample) |
| CA (1) | CA3250276A1 (enExample) |
| IL (1) | IL316848A (enExample) |
| MX (1) | MX2024013275A (enExample) |
| WO (1) | WO2023215910A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3183367A1 (en) | 2020-07-06 | 2022-01-13 | Gevorg GRIGORYAN | Antigen binding molecules targeting sars-cov-2 |
| CA3183373A1 (en) | 2020-07-06 | 2022-01-13 | Gevorg GRIGORYAN | Antigen binding molecules targeting sars-cov-2 |
| KR20230058434A (ko) | 2020-08-26 | 2023-05-03 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | SARS-CoV-2를 표적으로 하는 항원 결합 분자 |
| IL316848A (en) | 2022-05-06 | 2025-01-01 | Generate Biomedicines Inc | Antigen-binding molecules targeting SARS-CoV-2 |
| EP4581051A1 (en) * | 2022-08-31 | 2025-07-09 | Boost Biopharma, Inc. | Sars-cov-2 binding agents and uses thereof |
| JP2025537301A (ja) * | 2022-11-13 | 2025-11-14 | ジェネレイト バイオメディシンズ， インコーポレイテッド | Ｓａｒｓ－ｃｏｖ－２を標的とする抗原結合分子 |
| WO2025151836A1 (en) * | 2024-01-10 | 2025-07-17 | The Trustees Of Columbia University In The City Of New York | Antibodies against sarbecoviruses, their variants and uses thereof |
| WO2025235419A1 (en) | 2024-05-06 | 2025-11-13 | Generate Biomedicines, Inc. | Methods of treating or preventing sarbecovirus with antibodies or antigen-binding fragments thereof |
| WO2025235420A1 (en) * | 2024-05-06 | 2025-11-13 | Generate Biomedicines, Inc. | Methods of treating or preventing sarbecovirus with antibodies or antigen-binding fragments thereof |
| CN121299112B (zh) * | 2024-09-12 | 2026-04-17 | 中国食品药品检定研究院 | 一种检测九型hpv疫苗或抗原原液体外相对效力的方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004260884B2 (en) | 2003-07-22 | 2009-11-19 | Crucell Holland B.V. | Binding molecules against SARS-coronavirus and uses thereof |
| US7622112B2 (en) | 2003-12-05 | 2009-11-24 | Jody Berry | Anti-SARS monoclonal antibodies |
| SG159542A1 (en) | 2004-11-11 | 2010-03-30 | Crucell Holland Bv | Compositions against sars-coronavirus and uses thereof |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US9200079B2 (en) | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| KR101616758B1 (ko) | 2007-12-26 | 2016-04-29 | 젠코어 인코포레이티드 | ＦｃＲｎ에 대한 변경된 결합성을 갖는 Ｆｃ 변이체 |
| MY177098A (en) | 2013-08-09 | 2020-09-05 | Astellas Pharma Inc | Novel anti-human tslp receptor antibody |
| AR120698A1 (es) | 2019-12-09 | 2022-03-09 | Ablynx Nv | Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp |
| US20250263466A1 (en) | 2020-02-03 | 2025-08-21 | Vir Biotechnology, Inc. | Antibodies against sars-cov-2 and methods of using the same |
| WO2021156490A2 (en) | 2020-02-06 | 2021-08-12 | Vib Vzw | Corona virus binders |
| HUE062777T2 (hu) | 2020-02-26 | 2023-12-28 | Vir Biotechnology Inc | SARS-CoV-2 elleni antitestek |
| EP4121454A1 (en) | 2020-03-19 | 2023-01-25 | Imperial College Innovations Limited | Coronavirus antibody |
| US11028167B1 (en) | 2020-03-23 | 2021-06-08 | Centivax, Inc. | Anti-SARS-Cov-2 antibodies derived from 3bgf |
| CR20220552A (es) | 2020-04-02 | 2023-01-17 | Regeneron Pharma | Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno |
| WO2021203053A1 (en) | 2020-04-03 | 2021-10-07 | Vir Biotechnology, Inc. | Immunotherapy targeting a conserved region in sars coronaviruses |
| US20230348571A1 (en) | 2020-04-06 | 2023-11-02 | Vanderbilt University | Cross-reactive coronavirus antibodies and uses thereof |
| US11192940B2 (en) | 2020-04-10 | 2021-12-07 | Adagio Therapeutics, Inc. | Compounds specific to coronavirus S protein and uses thereof |
| BR112022020706A2 (pt) | 2020-04-14 | 2022-11-29 | Vir Biotechnology Inc | Anticorpos contra sars-cov-2 e métodos de uso dos mesmos |
| PH12022500020A1 (en) | 2020-05-08 | 2024-05-06 | Vir Biotechnology Inc | Antibodies against sars-cov-2 |
| CA3183373A1 (en) | 2020-07-06 | 2022-01-13 | Gevorg GRIGORYAN | Antigen binding molecules targeting sars-cov-2 |
| CA3183367A1 (en) | 2020-07-06 | 2022-01-13 | Gevorg GRIGORYAN | Antigen binding molecules targeting sars-cov-2 |
| WO2022015573A2 (en) * | 2020-07-13 | 2022-01-20 | President And Fellows Of Harvard College | Sars-cov-2 antigen-binding proteins and uses thereof |
| US20230058162A1 (en) | 2020-07-27 | 2023-02-23 | Igm Biosciences, Inc. | Multimeric coronavirus binding molecules and uses thereof |
| KR20230058434A (ko) | 2020-08-26 | 2023-05-03 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | SARS-CoV-2를 표적으로 하는 항원 결합 분자 |
| KR20230127305A (ko) * | 2020-12-29 | 2023-08-31 | 발-첨, 리미티드 파트너십 | Covid-19에 대한 중화 단일클론 항체 |
| EP4147716A1 (en) | 2021-09-10 | 2023-03-15 | Samatva Research Corporation | Anti-virus moiety immobilised in a matrix |
| IL316848A (en) | 2022-05-06 | 2025-01-01 | Generate Biomedicines Inc | Antigen-binding molecules targeting SARS-CoV-2 |
-
2023
- 2023-05-05 IL IL316848A patent/IL316848A/en unknown
- 2023-05-05 WO PCT/US2023/066714 patent/WO2023215910A1/en not_active Ceased
- 2023-05-05 EP EP23729919.3A patent/EP4519310A1/en active Pending
- 2023-05-05 CN CN202380048778.7A patent/CN121127489A/zh active Pending
- 2023-05-05 CA CA3250276A patent/CA3250276A1/en active Pending
- 2023-05-05 KR KR1020247040502A patent/KR20250054840A/ko active Pending
- 2023-05-05 JP JP2025513209A patent/JP2025515237A/ja active Pending
- 2023-05-05 AU AU2023265164A patent/AU2023265164A1/en active Pending
- 2023-05-05 US US18/313,306 patent/US11993644B2/en active Active
- 2023-05-08 US US18/314,091 patent/US20230357367A1/en not_active Abandoned
-
2024
- 2024-04-15 US US18/635,278 patent/US20240360203A1/en active Pending
- 2024-10-28 MX MX2024013275A patent/MX2024013275A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10544226B2 (en) | Antibody binding to FcRn for treating autoimmune diseases | |
| US20220002402A1 (en) | Methods of treating graves' ophthalmopathy using anti-fcrn antibodies | |
| JP2023549067A5 (enExample) | ||
| JP2010516229A5 (enExample) | ||
| RU2014148502A (ru) | Человеческие антитела к fel d1 и способы их применения | |
| JP2015514068A5 (enExample) | ||
| JP2023534923A5 (enExample) | ||
| AU2016334290B2 (en) | Antibody to hepatitis B surface antigen and use thereof | |
| IL269387A (en) | Pan-elr cxc chemokine antibodies | |
| CN116789832A (zh) | 抗4-1bb抗体及其制备和使用方法 | |
| JP2015503909A5 (enExample) | ||
| JP2023540037A5 (enExample) | ||
| JP2024506315A5 (enExample) | ||
| JP2018522540A5 (enExample) | ||
| JP2025514437A5 (enExample) | ||
| JP2022553922A5 (enExample) | ||
| JP2023534922A5 (enExample) | ||
| WO2022127793A1 (zh) | 呼吸道合胞病毒特异性结合分子 | |
| CN116715757A (zh) | 全人源抗狂犬病毒中和抗体及其用途 | |
| JP2003531866A (ja) | 抗体を用いた呼吸器疾患の組合せ治療法 | |
| JP2022527790A5 (enExample) | ||
| CN119768431A (zh) | Igf1r抗体 | |
| JP2023527059A5 (enExample) | ||
| JP2022530063A (ja) | 抗体製剤 | |
| JP2024544562A5 (enExample) |